Zydus Lifesciences Limited
NSE: CADILAHC
NSE
346.05
0.10 (0.03%)
Prev Close
345.95
Open Price
348.1
Volume
856,777
Today Low / High
344.75 / 351.45
52 WK Low / High
331.55 / 673.7
Range
329 - 363
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 346.05, with a change of 0.09997559 (0.02889885%). The expected target range on the NSE is between 329 - 363. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 346.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 346.05 | 349.51 | 314.56 - 384.46 |
| 352.97 | 282.38 - 423.57 | ||
| 356.43 | 249.50 - 463.36 | ||
| Bearish Scenario | 346.05 | 342.59 | 308.33 - 376.85 |
| 339.13 | 271.30 - 406.95 | ||
| 335.67 | 234.97 - 436.37 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,110,492
Market Cap
0
Last Dividend
96.4500002
Official Website
IPO Date
1995-05-15
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of CADILAHC
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-07-29 | July 29, 21 | 3.5 | 3.5 | |||
| 2020-03-23 | March 23, 20 | 3.5 | 3.5 | 2020-03-24 | 2020-03-30 | 2020-03-11 |
| 2019-07-26 | July 26, 19 | 3.5 | 3.5 | |||
| 2018-07-31 | July 31, 18 | 3.5 | 3.5 | 2018-08-01 | 2018-08-18 | 2018-05-25 |
| 2017-03-16 | March 16, 17 | 3.2 | 3.2 | 2017-03-17 | 2017-04-06 | 2017-02-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 17,050.60 Cr | 10,249.80 Cr | 6,800.80 Cr | 0.3989 | 1,236.30 Cr | 0.00 Cr | 2,691.70 Cr | 1,960.30 Cr | 19.30 | 3,442.20 Cr | 0.1150 |
| 2022-03-31 | 15,062.90 Cr | 9,168.10 Cr | 5,894.80 Cr | 0.3913 | 1,040.60 Cr | 0.00 Cr | 2,425.80 Cr | 1,806.70 Cr | 17.65 | 3,671.00 Cr | 0.1199 |
| 2021-03-31 | 14,287.10 Cr | 8,217.40 Cr | 6,069.70 Cr | 0.4248 | 1,119.60 Cr | 472.10 Cr | 2,628.80 Cr | 2,133.60 Cr | 20.84 | 3,298.40 Cr | 0.1493 |
| 2020-03-31 | 14,027.10 Cr | 8,538.50 Cr | 5,488.60 Cr | 0.3913 | 1,097.40 Cr | 543.90 Cr | 1,925.30 Cr | 1,176.60 Cr | 11.49 | 2,524.50 Cr | 0.0839 |
| 2019-03-31 | 12,928.90 Cr | 7,846.20 Cr | 5,082.70 Cr | 0.3931 | 951.70 Cr | 339.60 Cr | 2,202.00 Cr | 1,848.80 Cr | 18.06 | 3,176.50 Cr | 0.1430 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 492.60 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 702.30 Cr | 3,579.10 Cr | 6,973.10 Cr | 71.90 Cr | 0.00 Cr | 1,362.60 Cr | 5,526.7000 Cr |
| 2022-03-31 | 1,106.90 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,114.00 Cr | 3,898.20 Cr | 6,562.50 Cr | 48.90 Cr | 16.10 Cr | 1,140.10 Cr | 7,826.8000 Cr |
| 2021-03-31 | 888.30 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,719.30 Cr | 3,378.30 Cr | 6,443.60 Cr | 43.20 Cr | 22.70 Cr | 845.70 Cr | 7,861.3000 Cr |
| 2020-03-31 | 964.90 Cr | 23,686.60 Cr | 11,976.20 Cr | 10,375.7000 Cr | 8,013.80 Cr | 7,048.90 Cr | 2,874.60 Cr | 6,258.10 Cr | 48.70 Cr | 7.60 Cr | 804.70 Cr | 8,269.4000 Cr |
| 2019-03-31 | 649.30 Cr | 23,483.10 Cr | 11,803.90 Cr | 10,386.3000 Cr | 7,899.40 Cr | 7,250.10 Cr | 2,765.80 Cr | 6,070.60 Cr | 49.90 Cr | 6.70 Cr | 594.50 Cr | 7,342.5000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 2,640.2000 Cr | 1,093.6000 Cr | -4,274.2000 Cr | 1,609.3000 Cr | -614.3000 Cr | 492.6000 Cr | -1,030.9000 Cr | 1,964.9000 Cr | 0.0000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,052.0000 Cr | 1,095.4000 Cr | -757.2000 Cr | 849.4000 Cr | 218.6000 Cr | 1,106.9000 Cr | -1,202.6000 Cr | 2,241.6000 Cr | 0.0000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,158.7000 Cr | -773.4000 Cr | -2,363.7000 Cr | 2,304.7000 Cr | -76.6000 Cr | 888.3000 Cr | -854.0000 Cr | 2,201.6000 Cr | 0.0000 Cr | -1.5000 Cr | -479.7000 Cr |
| 2020-03-31 | 2,650.0000 Cr | -1,045.3000 Cr | -1,205.8000 Cr | 1,745.9000 Cr | 315.6000 Cr | 964.9000 Cr | -904.1000 Cr | 1,176.6000 Cr | 0.0000 Cr | -856.9000 Cr | -101.0000 Cr |
| 2019-03-31 | 2,856.4000 Cr | -5,792.3000 Cr | 1,964.1000 Cr | 1,799.0000 Cr | -665.6000 Cr | 649.3000 Cr | -1,057.4000 Cr | 1,848.8000 Cr | 0.0000 Cr | -431.4000 Cr | -100.4000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | 4,505.20 Cr | 2,480.60 Cr | 2,024.60 Cr | 0.4494 | 887.00 Cr | 789.60 Cr | 7.80 | 1,140.10 Cr | 0.1753 |
| 2023-09-30 | 4,368.80 Cr | 2,410.90 Cr | 1,957.90 Cr | 0.4482 | 879.70 Cr | 800.70 Cr | 7.91 | 1,200.10 Cr | 0.1833 |
| 2023-06-30 | 5,139.60 Cr | 2,584.60 Cr | 2,555.00 Cr | 0.4971 | 1,352.60 Cr | 1,086.90 Cr | 10.74 | 1,532.40 Cr | 0.2115 |
| 2023-03-31 | 5,010.60 Cr | 2,598.50 Cr | 2,412.10 Cr | 0.4814 | 1,135.50 Cr | 296.60 Cr | 2.93 | 692.10 Cr | 0.0592 |
| 2022-12-31 | 4,362.30 Cr | 2,381.00 Cr | 1,981.30 Cr | 0.4542 | 774.40 Cr | 622.90 Cr | 6.15 | 994.50 Cr | 0.1428 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | 907.10 Cr | 612.40 Cr | 1,519.50 Cr | 3,917.60 Cr | 3,303.90 Cr | 9,928.20 Cr | 6,936.60 Cr | 25,879.40 Cr | 4,938.50 Cr |
| 2023-03-31 | 492.60 Cr | 699.80 Cr | 1,192.40 Cr | 4,635.30 Cr | 3,579.10 Cr | 10,008.20 Cr | 6,973.10 Cr | 25,756.40 Cr | 6,068.10 Cr |
| 2022-09-30 | 783.70 Cr | 200.80 Cr | 984.50 Cr | 3,724.80 Cr | 3,404.70 Cr | 9,667.10 Cr | 6,722.00 Cr | 25,629.30 Cr | 6,861.80 Cr |
| 2021-09-30 | 375.10 Cr | 4,079.50 Cr | 4,454.60 Cr | 0.00 Cr | 3,518.80 Cr | 12,398.00 Cr | 6,213.80 Cr | 27,471.20 Cr | 9,295.60 Cr |
| 2021-03-31 | 665.20 Cr | 462.00 Cr | 1,127.20 Cr | 0.00 Cr | 3,236.20 Cr | 8,716.00 Cr | 6,443.60 Cr | 23,884.70 Cr | 8,955.10 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | 767.80 Cr | 389.60 Cr | 0.00 Cr | 0.00 Cr | 389.60 Cr | 1,296.70 Cr | 907.10 Cr | 0.00 Cr | 389.60 Cr |
| 2023-09-30 | 801.70 Cr | 368.40 Cr | 0.00 Cr | 0.00 Cr | 368.40 Cr | 907.10 Cr | 538.70 Cr | 0.00 Cr | 368.40 Cr |
| 2023-06-30 | 1,087.90 Cr | 359.60 Cr | 0.00 Cr | 0.00 Cr | 359.60 Cr | 852.20 Cr | 492.60 Cr | 0.00 Cr | 359.60 Cr |
| 2023-03-31 | 298.80 Cr | 357.20 Cr | 0.00 Cr | 0.00 Cr | 357.20 Cr | 492.60 Cr | 135.40 Cr | 0.00 Cr | 357.20 Cr |
| 2022-12-31 | 622.50 Cr | 363.20 Cr | 0.00 Cr | 0.00 Cr | 363.20 Cr | 1,146.90 Cr | 783.70 Cr | 0.00 Cr | 363.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,805.00 | ₹4,330,799,620,850.00 | ₹1,777,401.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,486.00 | ₹1,721,829,209,880.00 | ₹148,911.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,776.10 | ₹1,278,003,825,984.00 | ₹197,257.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,276.00 | ₹1,062,285,981,900.00 | ₹1,036,082.00 |
| Lupin Limited | LUPIN | ₹2,090.00 | ₹954,632,956,200.00 | ₹971,873.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹932.70 | ₹938,514,442,473.00 | ₹892,186.00 |
| Mankind Pharma Limited | MANKIND | ₹2,205.00 | ₹910,235,174,940.00 | ₹299,678.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,217.90 | ₹707,358,296,652.00 | ₹394,525.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,685.00 | ₹679,727,025,000.00 | ₹117,812.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,026.50 | ₹554,162,781,423.00 | ₹936,977.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,958.00 | ₹552,549,184,022.00 | ₹420,804.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,445.00 | ₹366,602,595,010.00 | ₹237,723.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,639.00 | ₹329,705,111,736.00 | ₹83,802.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,829.00 | ₹286,509,192,000.00 | ₹124,874.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,398.10 | ₹265,030,612,591.00 | ₹122,772.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,226.50 | ₹230,662,500,000.00 | ₹4,345.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,348.60 | ₹219,136,939,113.00 | ₹5,339,868.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,805.00 | ₹215,606,284,645.00 | ₹31,420.00 |
| Eris Lifesciences Limited | ERIS | ₹1,562.50 | ₹212,838,892,188.00 | ₹55,130.00 |
| Cohance Lifesciences Limited | COHANCE | ₹540.00 | ₹206,586,255,600.00 | ₹345,767.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹900.00 | ₹176,906,811,600.00 | ₹62,002.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,073.70 | ₹170,179,769,660.00 | ₹78,154.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹934.70 | ₹167,413,995,489.00 | ₹838,020.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,954.00 | ₹148,526,853,984.00 | ₹58,334.00 |
| Granules India Limited | GRANULES | ₹562.95 | ₹136,610,353,672.00 | ₹2,352,948.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹884.80 | ₹108,548,456,710.00 | ₹184,287.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,685.00 | ₹94,367,486,670.00 | ₹6,387.00 |
| Strides Pharma Science Limited | STAR | ₹880.40 | ₹81,148,857,406.00 | ₹127,046.00 |
| FDC Limited | FDC | ₹417.00 | ₹67,891,805,028.00 | ₹43,781.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹720.50 | ₹65,311,375,327.00 | ₹143,818.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹331.00 | ₹64,737,581,096.00 | ₹102,130.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹419.50 | ₹64,226,313,331.00 | ₹79,131.00 |
| Sequent Scientific Limited | SEQUENT | ₹200.15 | ₹50,002,237,373.00 | ₹2,136,594.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.50 | ₹49,489,542,170.00 | ₹15,956,517.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹865.50 | ₹43,897,385,378.00 | ₹52,567.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹378.85 | ₹41,281,490,645.00 | ₹113,620.00 |
| Innova Captab Limited | INNOVACAP | ₹707.05 | ₹40,460,886,049.00 | ₹6,208.00 |
| Suven Life Sciences Limited | SUVEN | ₹168.40 | ₹37,116,372,926.00 | ₹265,127.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹405.00 | ₹36,964,350,000.00 | ₹151,643.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,198.00 | ₹36,352,754,970.00 | ₹4,548.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹352.00 | ₹35,299,442,112.00 | ₹30,343.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹447.25 | ₹31,488,971,688.00 | ₹4,827.00 |
| Hikal Limited | HIKAL | ₹241.20 | ₹29,740,140,900.00 | ₹3,729,885.00 |
Key Executives
No executive data available.
FAQs about Zydus Lifesciences Limited
What is the current market price of the stock?
The current price is ₹346.05.
What is the 52-week price range?
The range is ₹344.75-351.45.
What is the dividend yield?
The dividend yield is 1.18%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 19.08.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹0.00 crores and an average daily volume of 2,110,492 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹96.4500002.